<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of children with non-chemotherapy-induced neutropenia and fever</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of children with non-chemotherapy-induced neutropenia and fever</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of children with non-chemotherapy-induced neutropenia and fever</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nabil M Ahmed, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Debra L Palazzi, MD, MEd</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter Newburger, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Children with fever and neutropenia should be evaluated promptly because fever may be the first manifestation of a life-threatening infection. The risk of infection in children with non-chemotherapy-induced neutropenia varies with the underlying cause of neutropenia  (<a class="graphic graphic_table graphicRef65091" href="/z/d/graphic/65091.html" rel="external">table 1</a>).</p><p>The management of children with non-chemotherapy-induced neutropenia and fever is reviewed here. The conditions that cause neutropenia in children, the risk of infection in and evaluation of children with non-chemotherapy-induced neutropenia and fever, and the evaluation and management children with chemotherapy-induced neutropenia and fever are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6058.html" rel="external">"Evaluation of children with non-chemotherapy-induced neutropenia and fever"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6051.html" rel="external">"Fever in children with chemotherapy-induced neutropenia"</a>.)</p><p></p><p class="headingAnchor" id="H6211742"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutropenia</strong> – In patients with non-chemotherapy-induced neutropenia, neutropenia is generally defined as an absolute neutrophil count (ANC) &lt;1500 cells/microL. The ANC is calculated using the following formula (<a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">calculator 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ANC = total white blood cell count (cells/microL) x (percent polymorphonuclear cells + percent bands) ÷ 100</p><p></p><p class="bulletIndent1">Increased risk of infection, primarily bacterial infection in those with only granulocyte-line deficiency, becomes apparent when the ANC is &lt;1000 cells/microL and rises as the ANC falls. (See  <a class="medical medical_review" href="/z/d/html/6058.html" rel="external">"Evaluation of children with non-chemotherapy-induced neutropenia and fever", section on 'Definitions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fever</strong> – In neutropenic patients, fever is defined as a single oral temperature ≥38.3°C (101°F), a temperature ≥38°C (100.4°F) for longer than one hour, or two elevations &gt;38°C (100.4°F) during a 12-hour period [<a href="#rid1">1-3</a>].</p><p></p><p class="bulletIndent1">The measurement and interpretation of temperature in children with non-chemotherapy-induced neutropenia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6058.html" rel="external">"Evaluation of children with non-chemotherapy-induced neutropenia and fever", section on 'Definitions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complicated febrile illness </strong>– Complicated febrile illness is defined by one or more of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemodynamic instability</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastrointestinal symptoms:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Abdominal pain</p><p class="bulletIndent3"><span class="glyph">-</span>Nausea</p><p class="bulletIndent3"><span class="glyph">-</span>Vomiting</p><p class="bulletIndent3"><span class="glyph">-</span>Diarrhea</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>New-onset neurologic signs or mental status changes</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravascular catheter infection (especially catheter tunnel infection)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Underlying chronic lung disease (eg, in children with dyskeratosis congenita or cartilage-hair hypoplasia)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>New pulmonary infiltrate or hypoxemia</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Skin or soft tissue infection at any site</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sinus tenderness or other findings of upper respiratory tract infection</p><p></p><p class="headingAnchor" id="H6213838"><span class="h1">RISK-BASED MANAGEMENT APPROACH</span><span class="headingEndMark"> — </span>The management of children with non-chemotherapy-induced neutropenia and fever varies with their risk of infection  (<a class="graphic graphic_table graphicRef65091" href="/z/d/graphic/65091.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/6058.html" rel="external">"Evaluation of children with non-chemotherapy-induced neutropenia and fever", section on 'Risk categorization'</a>.)</p><p>Given the lack of comparative clinical studies in children of non-chemotherapy-induced neutropenia, our approach is largely extrapolated from controlled clinical trials and guidelines for neutropenia and fever in children with cancer or hematopoietic cell transplant [<a href="#rid3">3,4</a>].</p><p class="headingAnchor" id="H336040664"><span class="h2">Low risk</span><span class="headingEndMark"> — </span>We consider the following children with neutropenia and fever to be at low risk of serious infection  (<a class="graphic graphic_table graphicRef65091" href="/z/d/graphic/65091.html" rel="external">table 1</a>) (see  <a class="medical medical_review" href="/z/d/html/6058.html" rel="external">"Evaluation of children with non-chemotherapy-induced neutropenia and fever", section on 'Low risk'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children with transient neutropenia</strong> – Otherwise healthy, well-appearing children with transient isolated neutropenia (eg, presumed to be related to an intercurrent infection; associated with medications such as antibiotics).</p><p></p><p class="bulletIndent1">Well-appearing children with transient, isolated neutropenia and fever usually are managed in the same manner as children without neutropenia, typically in the outpatient setting (unless the neutropenia was detected during hospitalization). In most cases, the neutropenia is associated with a presumed viral infection and resolves within one to two weeks [<a href="#rid5">5-9</a>].</p><p></p><p class="bulletIndent1">Management includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral antibiotics as indicated if the child has or develops localized bacterial infection (eg, acute otitis media, skin infection).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Follow-up with blood counts, usually within a few weeks, to ensure that the neutropenia resolves. Neutropenia that is discovered during the course of an infection may be the initial presentation of chronic neutropenia or hematologic malignancy [<a href="#rid6">6,10-12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children with chronic autoimmune neutropenia</strong> – Children with chronic autoimmune neutropenia (also known as chronic idiopathic neutropenia and chronic benign neutropenia) have a low risk of infection. They typically present with mild infections (eg, upper respiratory tract infection, otitis media, skin infection) but may (very rarely) develop serious bacterial infections (eg, pneumonia, meningitis, sepsis).</p><p></p><p class="bulletIndent1">Management includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral antibiotics as indicated for suspected bacterial infections in children with adequate bone marrow reserves, although hospitalization and parenteral antibiotics are usually warranted for skin and soft tissue infections.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hospitalization and parenteral antibiotics for children with a complicated febrile illness  (<a class="graphic graphic_table graphicRef130056" href="/z/d/graphic/130056.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individualized management for children with a history of complicated febrile illness.</p><p></p><p class="headingAnchor" id="H819305107"><span class="h2">Low-to-moderate risk</span><span class="headingEndMark"> — </span>We consider the children with cyclic neutropenia to be at low-to-moderate risk of serious infection if they are well appearing  (<a class="graphic graphic_table graphicRef65091" href="/z/d/graphic/65091.html" rel="external">table 1</a>):</p><p>The management of children at low-to-moderate risk varies with clinical findings  (<a class="graphic graphic_table graphicRef65091" href="/z/d/graphic/65091.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Those who have superficial skin infection, upper respiratory infections, may be treated in the outpatient setting with oral antibiotics (as clinically indicated) and close outpatient follow-up [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Those who have gingivitis or oral ulcers usually are treated symptomatically (eg, with topical therapies, including topical anesthetics and maintenance of mouth hygiene).</p><p></p><p class="bulletIndent1">In addition, children with cyclic neutropenia and oral ulcers or gingivitis generally are treated with granulocyte colony-stimulating factor to raise the absolute neutrophil count. (See  <a class="medical medical_review" href="/z/d/html/8370.html" rel="external">"Cyclic neutropenia", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Those who have a complicated febrile illness  (<a class="graphic graphic_table graphicRef130056" href="/z/d/graphic/130056.html" rel="external">table 2</a>) generally warrant hospitalization for broad-spectrum parenteral antibiotics. Complicated febrile illness should prompt consideration of a more serious form of neutropenia; it is very rare in children with conditions associated with low-to-moderate risk  (<a class="graphic graphic_table graphicRef65091" href="/z/d/graphic/65091.html" rel="external">table 1</a>), although clostridial sepsis may occur in children with cyclic neutropenia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Those with a past history of complicated febrile illness are managed on a case-by-case basis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Those with cyclic neutropenia and a fever pattern that is uncharacteristic or mucocutaneous lesions that are atypical for their neutrophil nadir are managed on a case-by-case basis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Those with cyclic neutropenia and abdominal pain are hospitalized for parenteral antibiotic therapy [<a href="#rid2">2</a>]. (See <a class="local">'Gastrointestinal symptoms'</a> below.)</p><p></p><p>The choice of antibiotics for hospitalized children varies with the clinical presentation. (See <a class="local">'Suggested initial regimens'</a> below.)</p><p class="headingAnchor" id="H1724259567"><span class="h2">High risk</span><span class="headingEndMark"> — </span>We consider the following children with non-chemotherapy-induced neutropenia to be at high risk of serious infection  (<a class="graphic graphic_table graphicRef65091" href="/z/d/graphic/65091.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Those who are ill appearing (eg, listless, confused, clinically deteriorating), whether or not they are febrile.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Well- or ill-appearing children with severe congenital neutropenia and fever. (See  <a class="medical medical_review" href="/z/d/html/8373.html" rel="external">"Congenital neutropenia", section on 'Severe congenital neutropenia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Well- or ill-appearing children with acquired or inherited aplastic anemia (eg, Fanconi anemia, Shwachman-Diamond syndrome) and fever.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Well- or ill-appearing children with other bone marrow failure syndromes (eg, cartilage-hair hypoplasia, reticular dysgenesis).</p><p></p><p>The cornerstone of treatment for the child with neutropenia who is high risk for serious infection is hospitalization for prompt initiation of empiric broad-spectrum parenteral antibiotic therapy pending results of blood cultures or cultures of specimens related to their symptomatic presentation. (See <a class="local">'Suggested initial regimens'</a> below.)</p><p class="headingAnchor" id="H2119481467"><span class="h1">ANTIMICROBIAL THERAPY FOR HOSPITALIZED CHILDREN</span></p><p class="headingAnchor" id="H9"><span class="h2">Spectrum of activity</span><span class="headingEndMark"> — </span>Empiric antibiotic therapy for children with non-chemotherapy-induced neutropenia and fever should be active against a broad spectrum of potential gram-positive and gram-negative pathogens (eg, <em>Pseudomonas aeruginosa</em>) [<a href="#rid14">14</a>].</p><p>Clinical factors that may influence the antimicrobial spectrum include (see <a class="local">'Suggested initial regimens'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Patient's clinical status (eg, hemodynamic stability, site of symptoms, decreased or decreasing glomerular filtration rate [GFR] or hepatic dysfunction)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug allergies (if any)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cause and presentation of previous life-threatening infection(s)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prophylactic antimicrobials (if the child is receiving prophylactic antimicrobials, the antimicrobial agent that is used for prophylaxis is avoided in the treatment regimen)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Previous colonization with resistant bacteria (eg, methicillin-resistant <em>Staphylococcus aureus </em>[MRSA]; vancomycin-resistant <em>Enterococcus;</em> extended-spectrum beta-lactamase [ESBL]-producing gram-negative organisms, including <em>Klebsiella pneumoniae</em>;<em> </em>carbapenemase-producing bacteria)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The types of bacterial isolates found in the institution and the community</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Local antibiotic susceptibility patterns</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Suggested initial regimens</span></p><p class="headingAnchor" id="H4027185813"><span class="h3">Uncomplicated febrile illness</span><span class="headingEndMark"> — </span>For uncomplicated febrile illness  (<a class="graphic graphic_table graphicRef130056" href="/z/d/graphic/130056.html" rel="external">table 2</a>) in hospitalized children with non-chemotherapy-induced neutropenia  (<a class="graphic graphic_table graphicRef65091" href="/z/d/graphic/65091.html" rel="external">table 1</a>), we suggest empiric monotherapy with a broad-spectrum antipseudomonal agent  (<a class="graphic graphic_table graphicRef130058" href="/z/d/graphic/130058.html" rel="external">table 3</a>).</p><p>Acceptable empiric monotherapy regimens include <strong>one of the following</strong> (the doses must be adjusted for decreased or decreasing GFR):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">Cefepime</a> – 50 mg/kg (to a maximum of 2 g per dose) intravenously (IV) every eight hours</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A carbapenem (eg, <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">meropenem</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">Meropenem</a> (for children ≥3 months of age) 20 mg/kg IV every eight hours (maximum of 1 g per dose)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">Piperacillin-tazobactam</a> (dosed according to the <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">piperacillin</a> component):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>&lt;2 months of age – 80 mg/kg IV every six hours</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>2 to 9 months of age – 80 mg/kg IV every eight hours</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>&gt;9 months of age</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Body weight &lt;40 kg – 100 mg/kg IV every six to eight hours (maximum of 16 g per day)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Body weight ≥40 kg – 3 g IV every six hours; this regimen aims to optimize drug levels for organisms with higher minimum inhibitory concentrations (MICs) [<a href="#rid15">15</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">Ceftazidime</a> 50 mg/kg IV every eight hours (maximum dose 2 g) is another option for children at low-to-moderate risk  (<a class="graphic graphic_table graphicRef65091" href="/z/d/graphic/65091.html" rel="external">table 1</a>) who are hospitalized because of a past history of complicated febrile illness. Ceftazidime is no longer recommended for high-risk patients because of its decreased activity against many gram-negative pathogens and weak activity against viridans streptococci.</p><p></p><p>Randomized trials and meta-analyses of randomized trials have demonstrated that monotherapy with such broad-spectrum antibiotics as <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a>, <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">meropenem</a>, or <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">piperacillin-tazobactam</a> is as efficacious as combination therapy for the empiric treatment of most febrile neutropenic patients [<a href="#rid16">16-21</a>].</p><p class="headingAnchor" id="H84649024"><span class="h3">Signs of sepsis</span><span class="headingEndMark"> — </span>For children with non-chemotherapy-induced neutropenia and signs of sepsis (eg, hypotension, unexplained tachycardia and/or widened pulse pressure, mental status changes, respiratory dysfunction), consultation with an expert in pediatric critical care and infectious diseases is suggested, and the empiric regimen is individualized according to institutional clinical practice guidelines and clinical features, including previous culture results, concern for multidrug-resistant organisms, local culture yields, and resistance patterns [<a href="#rid22">22</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>For children with no history of multidrug-resistant organisms, we provide broad-spectrum antipseudomonal therapy with <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children with a history of multidrug-resistant organisms, we provide broad-spectrum antipseudomonal therapy with <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">meropenem</a> or a novel beta-lactamase inhibitor combination (eg, <a class="drug drug_pediatric" data-topicid="121356" href="/z/d/drug information/121356.html" rel="external">ceftazidime-avibactam</a>, <a class="drug drug_pediatric" data-topicid="138674" href="/z/d/drug information/138674.html" rel="external">ceftolozane-tazobactam</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children with a history of or concern for carbapenem-resistant<em> Enterobacterales</em>, we provide broad-spectrum therapy with a novel beta-lactamase inhibitor combination (eg, <a class="drug drug_pediatric" data-topicid="121356" href="/z/d/drug information/121356.html" rel="external">ceftazidime-avibactam</a>).</p><p></p><p class="headingAnchor" id="H25528788"><span class="h3">Gastrointestinal symptoms</span><span class="headingEndMark"> — </span>For the hemodynamically stable child with neutropenia and abdominal symptoms, particularly abdominal pain or blood per rectum, we suggest that empiric therapy include activity against anaerobes.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abdominal symptoms</strong> – Acceptable empiric regimens include <strong>one of the following </strong>(the doses must be adjusted for renal dysfunction)  (<a class="graphic graphic_table graphicRef130058" href="/z/d/graphic/130058.html" rel="external">table 3</a>) [<a href="#rid3">3,23</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">Meropenem</a> (for children ≥3 months of age) 20 mg/kg IV every eight hours (maximum of 1 g per dose)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">Piperacillin-tazobactam</a> (dosed according to the <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">piperacillin</a> component)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>&lt;2 months of age – 80 mg/kg IV every six hours</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>2 to 9 months of age – 80 mg/kg IV every eight hours</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>&gt;9 months of age – Body weight &lt;40 kg: 100 mg/kg IV every six to eight hours (maximum of 16 g per day); body weight ≥40 kg: 3 g IV every 6 hours; this regimen aims to optimize drug levels for organisms with higher MICs</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Combination therapy with <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a> 50 mg/kg (to a maximum of 2 g per dose) IV every eight hours <strong>and</strong> <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">metronidazole</a> 10 to 13.3 mg/kg (to a maximum of 500 mg per dose) IV every eight hours</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suspected </strong><strong><em>Clostridioides</em></strong><strong> </strong><strong><em>difficile</em></strong> – For children with suspected <em>C.</em> <em>difficile</em>, we suggest combination therapy with a broad-spectrum antipseudomonal agent (eg, <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">meropenem</a>, <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a> with <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">metronidazole</a>) <strong>plus</strong> therapy for <em>C. difficile</em>, pending results of <em>C. difficile</em> testing. The therapy for <em>C. difficile</em> varies with the clinical scenario and is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6050.html" rel="external">"<i>Clostridioides difficile</i> infection in children: Treatment and outcome"</a>.)</p><p></p><p class="headingAnchor" id="H1281383889"><span class="h3">Other indications for combination therapy</span><span class="headingEndMark"> — </span>Extrapolating from guidelines for patients with chemotherapy-induced neutropenia and fever [<a href="#rid3">3,4,24</a>], we suggest increasing gram-positive coverage, typically by <strong>adding one of the following agents</strong> to broad-spectrum antipseudomonal therapy (eg, <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">meropenem</a>, or <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a>), in the clinical scenarios listed below  (<a class="graphic graphic_table graphicRef130058" href="/z/d/graphic/130058.html" rel="external">table 3</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Radiographically documented pneumonia – Add <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> if MRSA is suspected  (<a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of meningitis or new onset of neurologic signs and symptoms suggestive of meningitis – Add <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a>  (<a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">table 4</a>) to broad-spectrum antipseudomonal therapy with <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a> or <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">meropenem</a>; if meropenem is used as the broad-spectrum antipseudomonal agent, use the dose for central nervous system infections: 40 mg/kg IV every eight hours (maximum of 2 g per dose).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinically suspected central venous catheter site infection (eg, chills or rigors with infusion through the catheter and signs of infection around the catheter entry or exit site) – Add <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a>  (<a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">table 4</a>) to broad-spectrum antipseudomonal therapy [<a href="#rid25">25</a>]. Alternatives to vancomycin include <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">ceftaroline</a> or <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">daptomycin</a>, although these agents are not used routinely.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For any of the following, add <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a>  (<a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">table 4</a>), <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> (if the rates of clindamycin-resistant <em>S. aureus</em> in the community is acceptably low and the child is not receiving <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">meropenem</a> or <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">piperacillin-tazobactam</a>), or <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">linezolid</a> (if the child is known to be colonized with or has a history of infection with vancomycin-resistant gram-positive organisms; linezolid should be used with caution because it has been associated with neutropenia) [<a href="#rid3">3,26</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Skin or soft tissue infection at any site (eg, cellulitis) [<a href="#rid27">27</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Known colonization with MRSA or penicillin- and cephalosporin-resistant <em>Streptococcus pneumoniae </em>or previous history of infection with penicillin-resistant streptococci [<a href="#rid28">28</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High prevalence of MRSA infections in the community</p><p></p><p>When broadening gram-positive coverage, the combination of <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> and <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">piperacillin-tazobactam</a> should be avoided because of the increased risk of acute kidney injury [<a href="#rid29">29,30</a>]. Kidney function should be monitored in children receiving vancomycin.</p><p>The routine use of empiric <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> or other agents with gram-positive activity for febrile neutropenia is discouraged to decrease colonization or infection with multidrug-resistant organisms, such as vancomycin-resistant enterococci, and to prevent complications of overuse, such as <em>C. difficile</em> colitis. In addition, although up to two-thirds of bacterial bloodstream isolates in febrile neutropenic cancer patients are gram-positive cocci (frequently coagulase-negative staphylococci resistant to beta-lactams, except <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">ceftaroline</a>), in randomized trials, the morbidity and mortality were similar for cancer patients with fever and neutropenia who were treated with and without vancomycin in the initial antibiotic regimen [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H7428430"><span class="h2">Ongoing antimicrobial therapy</span><span class="headingEndMark"> — </span>Modification of the initial empiric antimicrobial regimen may be necessary in children with clinical worsening or instability, documented infection, or persistent unexplained fever.</p><p class="headingAnchor" id="H349611293"><span class="h3">Clinical worsening or instability</span><span class="headingEndMark"> — </span>Children who worsen or become unstable at any point during antimicrobial therapy should undergo reevaluation for new or worsening sites of infection. Reevaluation includes thorough physical examination and imaging or repeat imaging, as well as culture, biopsy, or drainage of sites of worsening or potential new infection (assessing for bacterial, viral, and fungal pathogens). (See  <a class="medical medical_review" href="/z/d/html/6058.html" rel="external">"Evaluation of children with non-chemotherapy-induced neutropenia and fever", section on 'Evaluation'</a>.)</p><p>Antimicrobial therapy should be reviewed for adequacy of dosing and spectrum.</p><p>For children with hemodynamic instability and no identified source of fever, antimicrobial therapy should be broadened (eg, to increase activity against gram-positive, gram-negative, resistant, and potentially anaerobic bacteria). Appropriate regimens vary with the clinical scenario, local susceptibility data, and institutional formulary.</p><p class="headingAnchor" id="H3057956564"><span class="h3">Positive blood culture</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolation of gram-negative bacteria pending identification and susceptibility </strong>–<strong> </strong>The antimicrobial regimen should be adjusted when susceptibility results are available. There is no need to add another agent with activity against gram-negative organisms if the patient is stable. In a retrospective review of 879 children with gram-negative bacteremia, compared with beta-lactam monotherapy, combination beta-lactam/aminoglycoside therapy that continued after susceptibility results were available was not associated with improved 30-day mortality (approximately 7 percent in both groups) but was associated with increased rates of nephrotoxicity (25 versus 10 percent) [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolation of gram-positive bacteria pending identification and susceptibility</strong> – Add <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a>; alternative agents include <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">ceftaroline</a> and <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">daptomycin</a> if the patient is known to be colonized with or previously infected with vancomycin-resistant gram-positive organisms. The modified antimicrobial regimen should be adjusted when susceptibility results are available.</p><p></p><p class="headingAnchor" id="H2936922587"><span class="h3">Other documented infection</span><span class="headingEndMark"> — </span>For children with documented infection at any point during treatment, antimicrobial therapy is modified according to culture and susceptibility results and/or site of infection [<a href="#rid3">3</a>]. Infection may be documented microbiologically (eg, positive culture) or clinically (eg, cellulitis or pneumonia without isolated pathogen).</p><p class="headingAnchor" id="H115957807"><span class="h3">No documented infection</span><span class="headingEndMark"> — </span>For clinically stable children with no documented infection after 48 hours of antimicrobial therapy and resolution of fever, we <strong>recommend discontinuing</strong> antimicrobial agents and monitor clinically given the potential harms of ongoing therapy without a documented infection (eg, nephrotoxicity, colonization or infection with resistant pathogens) [<a href="#rid4">4</a>]. For clinically stable children with no documented infection at 48 hours of antimicrobial therapy who remain febrile, we <strong>recommend continuing antipseudomonal therapy</strong> (eg, <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a>, <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">meropenem</a>, <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">piperacillin-tazobactam</a>) while evaluating for a source of infection.</p><p>We make further modifications to the empiric antibiotic regimen only if clinical status changes (eg, clinical worsening, documented infection, as described above). We generally do not alter the antibiotic regimen for persistent fever or recurrence of fever after initial defervescence without additional changes in clinical status, although the addition of antifungal therapy may be warranted.</p><p class="headingAnchor" id="H14"><span class="h3">Addition of antifungal therapy</span><span class="headingEndMark"> — </span>For children with non-chemotherapy-induced neutropenia who have remained febrile and severely or profoundly neutropenic and have no indicators of count recovery after four to five days of broad-spectrum antibiotics, we suggest that antifungal therapy be added to the empiric antibiotic regimen, as is standard of care in chemotherapy-induced neutropenia.</p><p>Patients with persistent fever and neutropenia despite empiric antibacterial therapy may have a clinically occult fungal infection [<a href="#rid3">3,4</a>]. Addition of antifungal therapy is particularly important for patients with severe aplastic anemia, for whom invasive fungal infections, especially <em>Aspergillus</em>, are a major cause of death [<a href="#rid14">14,33</a>]. (See  <a class="medical medical_review" href="/z/d/html/6058.html" rel="external">"Evaluation of children with non-chemotherapy-induced neutropenia and fever", section on 'Aplastic anemia'</a>.)</p><p>There is little evidence to guide the choice of empiric antifungal agents for children with non-chemotherapy-induced neutropenia. Although antifungal agents are better studied in children with chemotherapy-induced neutropenia, comparative evidence of efficacy and safety is limited [<a href="#rid34">34,35</a>]. (See  <a class="medical medical_review" href="/z/d/html/6051.html" rel="external">"Fever in children with chemotherapy-induced neutropenia", section on 'Addition of antifungal therapy'</a>.)</p><p>Given the limited evidence, the choice of empiric antifungal agent for children with non-chemotherapy-induced neutropenia is influenced by age and potential adverse effects.</p><p class="bulletIndent1"><span class="glyph">●</span>Conventional amphotericin B (<a class="drug drug_pediatric" data-topicid="12647" href="/z/d/drug information/12647.html" rel="external">amphotericin B deoxycholate</a>) is active against a broad-spectrum of fungi and is a reasonable initial therapy for neonates and young infants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We generally prefer lipid formulations of amphotericin or an echinocandin that is active against yeasts and <em>Aspergillus</em> spp (eg, <a class="drug drug_pediatric" data-topicid="12713" href="/z/d/drug information/12713.html" rel="external">micafungin</a>) for older infants and children.</p><p></p><p>Alternative antifungal agents include other echinocandins (eg, <a class="drug drug_pediatric" data-topicid="12914" href="/z/d/drug information/12914.html" rel="external">caspofungin</a>, <a class="drug drug_pediatric" data-topicid="12713" href="/z/d/drug information/12713.html" rel="external">micafungin</a>) and triazole derivatives (eg, <a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">voriconazole</a>, <a class="drug drug_pediatric" data-topicid="12997" href="/z/d/drug information/12997.html" rel="external">posaconazole</a>). We generally avoid <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">fluconazole</a> because it is not active against <em>Aspergillus</em> spp. Of the triazoles, posaconazole and <a class="drug drug_pediatric" data-topicid="139000" href="/z/d/drug information/139000.html" rel="external">isavuconazole</a> have additional coverage against Zygomycetes and other filamentous fungi. (See  <a class="medical medical_review" href="/z/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Duration of therapy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identified source of infection</strong> – For children with an identified source of infection, the duration of antimicrobial therapy is determined by the site of infection (eg, pneumonia, cellulitis), the clinical response (including resolution of fever), and the pathogen identified. Antimicrobial agents that do not target the pathogenic organism can be stopped at this stage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unknown source of fever</strong> – When the source of the fever remains unknown, empiric antibiotic therapy (with the exception of agents that were added for additional gram-positive or gram-negative activity) usually is continued until fever resolves and, in certain cases, until bone marrow production of granulocytes has recovered. In select patients, empiric antibiotic therapy may be transferred to an ambulatory setting after an initial period of 48 hours [<a href="#rid3">3,4,13</a>]. (See <a class="local">'No documented infection'</a> above.)</p><p></p><p class="bulletIndent1">For children with aplastic anemia and other forms of stable chronic neutropenia, the indeterminate duration of neutropenia complicates the decision about the course of antibiotics. We generally continue antibiotics for a total of 14 days. Results of a sentinel study of infection in patients with aplastic anemia suggest that empiric antibiotic therapy should continue for 10 to 14 days, followed by careful observation [<a href="#rid14">14</a>]. The duration of antifungal therapy, if initiated, requires careful consideration because of the high risk of <em>Aspergillus</em> infection. Consultation with experts in pediatric hematology and infectious diseases is suggested.</p><p></p><p class="headingAnchor" id="H16"><span class="h1">GRANULOCYTE COLONY-STIMULATING FACTOR</span><span class="headingEndMark"> — </span>Decisions regarding initiation of granulocyte colony-stimulating factor (G-CSF; <a class="drug drug_pediatric" data-topicid="13301" href="/z/d/drug information/13301.html" rel="external">filgrastim</a>, lenograstim) in children with non-chemotherapy-induced neutropenia and complicated febrile illness requiring hospitalization are individualized. Previous infectious history of the patient, especially history of prior serious infection, needs to be considered. Such children should be treated in specialized centers by clinicians with expertise in the use of G-CSF. (See  <a class="medical medical_review" href="/z/d/html/8383.html" rel="external">"Introduction to recombinant hematopoietic growth factors"</a>.)</p><p></p><p>The benefits of initiation of G-CSF in children with non-chemotherapy-induced neutropenia and fever are unproven. Limited data suggest that prophylactic treatment with G-CSF may be beneficial in reducing episodes of fever and infection in children with cyclic neutropenia and congenital neutropenia [<a href="#rid36">36,37</a>]. The prophylactic use of G-CSF in the treatment of each of these disorders is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8371.html" rel="external">"Immune neutropenia", section on 'Chronic idiopathic neutropenia'</a> and  <a class="medical medical_review" href="/z/d/html/8370.html" rel="external">"Cyclic neutropenia", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/8373.html" rel="external">"Congenital neutropenia", section on 'Severe congenital neutropenia'</a>.)</p><p class="headingAnchor" id="H6213993"><span class="h1">ENVIRONMENTAL PRECAUTIONS</span><span class="headingEndMark"> — </span>Environmental precautions may reduce the risk of hospital-acquired infection in neutropenic patients who are admitted to the hospital for treatment of fever. Environmental precautions may include [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>All persons should perform hand hygiene before entering and after leaving the patient's room</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral hygiene (toothbrushing at least twice per day; oral rinses; dental flossing once per day if it can be performed without trauma)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Daily showers or baths</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Daily inspection of skin sites that may be portals of infection (eg, perineum, sites of intravascular access)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perineal hygiene (gentle but thorough cleaning after bowel movements; thorough drying of the perineum after urination)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of tampons</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of rectal procedures (eg, thermometry, enemas, suppositories, examinations)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prohibition of plants and dried or fresh flowers in the patient's room (may contain molds)</p><p></p><p>Although a "neutropenic diet" (eg, well-cooked foods; avoidance of prepared luncheon meats) has been recommended, it does not provide any benefit over adherence to the US Food and Drug Administration food safety guidelines [<a href="#rid38">38,39</a>] and may be nutritionally insufficient [<a href="#rid40">40</a>]. Adherence to a neutropenic diet is therefore not recommended.</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – Neutropenia is generally defined as an absolute neutrophil count (ANC) &lt;1500 cells/microL (<a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">calculator 1</a>). Increased risk of infection becomes apparent when the ANC is &lt;1000 cells/microL and rises as the ANC falls. In neutropenic patients, fever is defined as a single oral temperature ≥38.3°C (101°F), a temperature ≥38°C (100.4°F) for longer than one hour, or two elevations &gt;38°C (100.4°F) during a 12-hour period. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk-based management approach</strong> – Our approach to the management of children with non-chemotherapy-induced neutropenia and fever varies with their risk of infection and is summarized in the table  (<a class="graphic graphic_table graphicRef65091" href="/z/d/graphic/65091.html" rel="external">table 1</a>). (See <a class="local">'Risk-based management approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial antimicrobial therapy</strong> – Initial antimicrobial therapy for children hospitalized with non-chemotherapy-induced neutropenia varies with the clinical findings.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with uncomplicated febrile illness  (<a class="graphic graphic_table graphicRef130056" href="/z/d/graphic/130056.html" rel="external">table 2</a>), we suggest initial broad-spectrum monotherapy with an antipseudomonal antibiotic (eg, <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a>, <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">meropenem</a>, <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">piperacillin-tazobactam</a>) rather than combination therapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Uncomplicated febrile illness'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with signs of sepsis (eg, hypotension, unexplained tachycardia and/or widened pulse pressure, mental status changes, respiratory dysfunction), consultation with an expert in pediatric critical care and infectious diseases is suggested, and the empiric regimen is individualized according to institutional clinical practice guidelines, clinical features, including previous culture results, concern for multidrug resistant organisms, and local resistance patterns. (See <a class="local">'Signs of sepsis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with abdominal symptoms, particularly abdominal pain or blood per rectum, we suggest an antibiotic regimen with activity against anaerobes (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Acceptable regimens include monotherapy with <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">piperacillin-tazobactam</a> or <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">meropenem</a> or combination therapy with <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a> and <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">metronidazole</a>. (See <a class="local">'Gastrointestinal symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other indications for combination therapy and suggested regimens are provided in the table  (<a class="graphic graphic_table graphicRef130058" href="/z/d/graphic/130058.html" rel="external">table 3</a>). (See <a class="local">'Other indications for combination therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ongoing antimicrobial therapy</strong> – Modification of the initial empiric antibiotic regimen may be necessary in children with clinical worsening, instability, or development of documented infection (eg, positive blood culture). (See <a class="local">'Clinical worsening or instability'</a> above and <a class="local">'Positive blood culture'</a> above and <a class="local">'Other documented infection'</a> above.)</p><p></p><p class="bulletIndent1">For clinically stable children with no documented infection after 48 hours of antimicrobial therapy and resolution of fever, we discontinue antimicrobial therapy. For clinically stable children with no documented infection at 48 hours of antimicrobial therapy who remain febrile, we generally continue antipseudomonal therapy (eg, <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a>, <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">meropenem</a>, <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">piperacillin-tazobactam</a>) while evaluating for a source of infection. (See <a class="local">'No documented infection'</a> above.)</p><p></p><p class="bulletIndent1">We suggest that antifungal therapy be initiated in children who remain febrile and profoundly neutropenic after four days of broad-spectrum antibiotics (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Addition of antifungal therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of antimicrobial therapy</strong> – The duration of antimicrobial therapy is determined by the site of infection (eg, pneumonia, cellulitis), the clinical response (including resolution of fever), and the pathogen identified. When the source of the fever remains unknown, empiric antibiotic therapy (with the exception of agents that were added for additional gram-positive or gram-negative activity) usually is continued until clinical response (eg, resolution of fever) and, in certain cases, until bone marrow production of granulocytes has recovered. (See <a class="local">'Duration of therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Wolff LJ, Ablin AR, Altman AJ, Johnson FL. The management of fever. In: Supportive care of children with cancer: Current therapy and guidelines from the Children's Cancer Group, 2nd ed, Ablin AR (Ed), Johns Hopkins University Press, Baltimore 1997. p.23.</li><li><a class="nounderline abstract_t">Weinberger M. Approach to management of fever and infection in patients with primary bone marrow failure and hemoglobinopathies. Hematol Oncol Clin North Am 1993; 7:865.</a></li><li><a class="nounderline abstract_t">Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.</a></li><li><a class="nounderline abstract_t">Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. J Clin Oncol 2017; 35:2082.</a></li><li><a class="nounderline abstract_t">Jonsson OG, Buchanan GR. Chronic neutropenia during childhood. A 13-year experience in a single institution. Am J Dis Child 1991; 145:232.</a></li><li><a class="nounderline abstract_t">Alexandropoulou O, Kossiva L, Haliotis F, et al. Transient neutropenia in children with febrile illness and associated infectious agents: 2 years' follow-up. Eur J Pediatr 2013; 172:811.</a></li><li><a class="nounderline abstract_t">Husain EH, Mullah-Ali A, Al-Sharidah S, et al. Infectious etiologies of transient neutropenia in previously healthy children. Pediatr Infect Dis J 2012; 31:575.</a></li><li><a class="nounderline abstract_t">Karavanaki K, Polychronopoulou S, Giannaki M, et al. Transient and chronic neutropenias detected in children with different viral and bacterial infections. Acta Paediatr 2006; 95:565.</a></li><li><a class="nounderline abstract_t">Alario AJ, O'Shea JS. Risk of infectious complications in well-appearing children with transient neutropenia. Am J Dis Child 1989; 143:973.</a></li><li><a class="nounderline abstract_t">Serwint JR, Dias MM, Chang H, et al. Outcomes of febrile children presumed to be immunocompetent who present with leukopenia or neutropenia to an ambulatory setting. Clin Pediatr (Phila) 2005; 44:593.</a></li><li><a class="nounderline abstract_t">Pascual C, Trenchs V, Hernández-Bou S, et al. Outcomes and infectious etiologies of febrile neutropenia in non-immunocompromised children who present in an emergency department. Eur J Clin Microbiol Infect Dis 2016; 35:1667.</a></li><li><a class="nounderline abstract_t">Nagalapuram V, McCall D, Palabindela P, et al. Outcomes of Isolated Neutropenia Referred to Pediatric Hematology-Oncology Clinic. Pediatrics 2020; 146.</a></li><li><a class="nounderline abstract_t">Donadieu J, Fenneteau O, Beaupain B, et al. Congenital neutropenia: diagnosis, molecular bases and patient management. Orphanet J Rare Dis 2011; 6:26.</a></li><li><a class="nounderline abstract_t">Weinberger M, Elattar I, Marshall D, et al. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) 1992; 71:24.</a></li><li><a class="nounderline abstract_t">Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer 2009; 53:379.</a></li><li><a class="nounderline abstract_t">Paul M, Yahav D, Bivas A, et al. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev 2010; :CD005197.</a></li><li><a class="nounderline abstract_t">Viscoli C, Cometta A, Kern WV, et al. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect 2006; 12:212.</a></li><li><a class="nounderline abstract_t">Simon A, Lehrnbecher T, Bode U, et al. Piperacillin-tazobactam in pediatric cancer patients younger than 25 months: a retrospective multicenter survey. Eur J Clin Microbiol Infect Dis 2007; 26:801.</a></li><li><a class="nounderline abstract_t">Sano H, Kobayashi R, Suzuki D, et al. A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders. Pediatr Blood Cancer 2017; 64.</a></li><li><a class="nounderline abstract_t">Manji A, Lehrnbecher T, Dupuis LL, et al. A meta-analysis of antipseudomonal penicillins and cephalosporins in pediatric patients with fever and neutropenia. Pediatr Infect Dis J 2012; 31:353.</a></li><li><a class="nounderline abstract_t">Manji A, Lehrnbecher T, Dupuis LL, et al. A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia. Support Care Cancer 2012; 20:2295.</a></li><li><a class="nounderline abstract_t">Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis 2021; 72:e169.</a></li><li><a class="nounderline abstract_t">Smith-Slatas CL, Bourque M, Salazar JC. Clostridium septicum infections in children: a case report and review of the literature. Pediatrics 2006; 117:e796.</a></li><li><a class="nounderline abstract_t">Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control 1995; 23:87.</a></li><li><a class="nounderline abstract_t">Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.</a></li><li><a class="nounderline abstract_t">Hakim H, Flynn PM, Knapp KM, et al. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2009; 31:623.</a></li><li><a class="nounderline abstract_t">Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59:147.</a></li><li><a class="nounderline abstract_t">Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25:247.</a></li><li><a class="nounderline abstract_t">Downes KJ, Cowden C, Laskin BL, et al. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children. JAMA Pediatr 2017; 171:e173219.</a></li><li><a class="nounderline abstract_t">Cook KM, Gillon J, Grisso AG, et al. Incidence of Nephrotoxicity Among Pediatric Patients Receiving Vancomycin With Either Piperacillin-Tazobactam or Cefepime: A Cohort Study. J Pediatric Infect Dis Soc 2019; 8:221.</a></li><li><a class="nounderline abstract_t">Beyar-Katz O, Dickstein Y, Borok S, et al. Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev 2017; 6:CD003914.</a></li><li><a class="nounderline abstract_t">Tamma PD, Turnbull AE, Harris AD, et al. Less is more: combination antibiotic therapy for the treatment of gram-negative bacteremia in pediatric patients. JAMA Pediatr 2013; 167:903.</a></li><li><a class="nounderline abstract_t">Torres HA, Bodey GP, Rolston KV, et al. Infections in patients with aplastic anemia: experience at a tertiary care cancer center. Cancer 2003; 98:86.</a></li><li><a class="nounderline abstract_t">Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29:415.</a></li><li><a class="nounderline abstract_t">Blyth CC, Hale K, Palasanthiran P, et al. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev 2010; :CD006343.</a></li><li><a class="nounderline abstract_t">Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81:2496.</a></li><li><a class="nounderline abstract_t">Dale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003; 72:82.</a></li><li><a class="nounderline abstract_t">Moody KM, Baker RA, Santizo RO, et al. A randomized trial of the effectiveness of the neutropenic diet versus food safety guidelines on infection rate in pediatric oncology patients. Pediatr Blood Cancer 2018; 65.</a></li><li><a class="nounderline abstract_t">Sonbol MB, Firwana B, Diab M, et al. The Effect of a Neutropenic Diet on Infection and Mortality Rates in Cancer Patients: A Meta-Analysis. Nutr Cancer 2015; 67:1230.</a></li><li><a class="nounderline abstract_t">Maia JE, da Cruz LB, Gregianin LJ. Microbiological profile and nutritional quality of a regular diet compared to a neutropenic diet in a pediatric oncology unit. Pediatr Blood Cancer 2018; 65.</a></li></ol></div><div id="topicVersionRevision">Topic 6059 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Wolff LJ, Ablin AR, Altman AJ, Johnson FL. The management of fever. In: Supportive care of children with cancer: Current therapy and guidelines from the Children's Cancer Group, 2nd ed, Ablin AR (Ed), Johns Hopkins University Press, Baltimore 1997. p.23.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8354659" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Approach to management of fever and infection in patients with primary bone marrow failure and hemoglobinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258094" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28459614" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1994695" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chronic neutropenia during childhood. A 13-year experience in a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23408310" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Transient neutropenia in children with febrile illness and associated infectious agents: 2 years' follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22414904" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Infectious etiologies of transient neutropenia in previously healthy children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16825137" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Transient and chronic neutropenias detected in children with different viral and bacterial infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2756974" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Risk of infectious complications in well-appearing children with transient neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16151565" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Outcomes of febrile children presumed to be immunocompetent who present with leukopenia or neutropenia to an ambulatory setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27319003" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Outcomes and infectious etiologies of febrile neutropenia in non-immunocompromised children who present in an emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32883808" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Outcomes of Isolated Neutropenia Referred to Pediatric Hematology-Oncology Clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21595885" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Congenital neutropenia: diagnosis, molecular bases and patient management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1549057" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19422028" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21069685" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16451406" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17786491" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Piperacillin-tazobactam in pediatric cancer patients younger than 25 months: a retrospective multicenter survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27873451" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22173145" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A meta-analysis of antipseudomonal penicillins and cephalosporins in pediatric patients with fever and neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22138849" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33106864" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrumβ-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567392" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clostridium septicum infections in children: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7639408" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19489710" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19644403" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Etiology and clinical course of febrile neutropenia in children with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24947530" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9332520" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28973124" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29590376" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Incidence of Nephrotoxicity Among Pediatric Patients Receiving Vancomycin With Either Piperacillin-Tazobactam or Cefepime: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28577308" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23921724" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Less is more: combination antibiotic therapy for the treatment of gram-negative bacteremia in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12833460" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Infections in patients with aplastic anemia: experience at a tertiary care cancer center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20431381" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20166083" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8490166" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12555210" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28696047" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A randomized trial of the effectiveness of the neutropenic diet versus food safety guidelines on infection rate in pediatric oncology patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26400721" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The Effect of a Neutropenic Diet on Infection and Mortality Rates in Cancer Patients: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28960796" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Microbiological profile and nutritional quality of a regular diet compared to a neutropenic diet in a pediatric oncology unit.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
